Oncotype DX to be Included in NIH's Genetic Testing Registry

In response to continued advances in genomic technology and genetic medicine, the

National Institutes of Health

(NIH) has developed the Genetic Testing Registry (GTR), a free online resource, to provide physicians, researchers and patients with detailed and accurate information about genetic and genomic tests. Comprehensive scientific and clinical information about the Oncotype DX

breast cancer test is now incorporated in the GTR database, representing

Genomic Health's

leadership in applying genomic information to make cancer care smarter.

®

"Over the last decade, in partnership with many collaborators, we have demonstrated that the rigorous validation of genomic information can transform cancer treatment," said

Phil Febbo

, M.D., chief medical officer,

Genomic Health

. "As new discoveries about the human genome continue to inspire medical innovations, we are proud to share the breadth of our clinical evidence to showcase how world-class science can be translated into a practice-changing test like Oncotype DX."

Read the news release here:

http://bit.ly/1gDQLeS

Source: genomic Health